Locust Walk Company Profile

Background

Overview

Locust Walk is a global investment bank specializing in the life sciences sector, offering strategic advisory services to biopharmaceutical and medical technology companies. Established in 2008, the firm operates with a "Co-founder Mentality," partnering closely with founders, executives, and board members to drive strategic transactions and create new companies that finance innovation. With offices in Boston, San Francisco, Tokyo, and Beijing, Locust Walk has successfully closed over 80 transactions, underscoring its significant presence in the industry.

Mission and Vision

Locust Walk's mission is to advance innovative biopharmaceutical and medical technology companies by providing comprehensive strategic and financial advisory services. The firm's vision is to be the premier partner for life sciences companies, facilitating transformative deals that bring groundbreaking therapies and technologies to market.

Industry Significance

As a dedicated life sciences investment bank, Locust Walk plays a crucial role in bridging the gap between scientific innovation and commercial success. Its expertise in navigating complex transactions and its deep understanding of the biopharmaceutical and medtech landscapes make it a valuable ally for companies seeking to optimize their strategic and financial outcomes.

Key Strategic Focus

Core Objectives

Locust Walk focuses on delivering integrated corporate development solutions, encompassing strategy consulting, market analytics, and transaction execution. The firm's objectives include:

• Strategic Transactions: Advising on mergers, acquisitions, licensing agreements, and other strategic partnerships to enhance client portfolios.

• Capital Raising: Assisting in securing funding through various channels, including venture capital, private equity, and public markets.

• NewCo Creation: Collaborating with clients to establish new companies, leveraging capital relationships and strategic insights to foster innovation.

Areas of Specialization

Locust Walk specializes in several key areas:

• Biopharmaceuticals: Guiding companies through the complexities of drug development, regulatory approvals, and market entry strategies.

• Medical Technologies: Providing support for medical device and diagnostics companies, from product development to commercialization.

• Digital Health: Advising on the integration of technology into healthcare solutions, including telemedicine and health IT.

Key Technologies Utilized

The firm employs advanced market analytics and strategic modeling tools to inform decision-making and optimize transaction outcomes. Additionally, Locust Walk has integrated AI-driven platforms to enhance due diligence processes and accelerate deal execution.

Primary Markets Targeted

Locust Walk serves a global clientele, with a particular emphasis on markets in the United States, Japan, China, and Europe. The firm's local presence in key biopharma hubs enables it to effectively navigate regional dynamics and facilitate cross-border transactions.

Financials and Funding

Funding History

As a privately held firm, Locust Walk has not publicly disclosed detailed funding information. However, the company has demonstrated financial stability and growth through its extensive transaction history and global expansion.

Recent Funding Rounds

Specific details regarding recent funding rounds are not publicly available. The firm's financial strategy focuses on organic growth and reinvestment into its service offerings and global operations.

Notable Investors

While individual investors are not publicly disclosed, Locust Walk's strategic partnerships and collaborations with leading biopharmaceutical companies and venture capital firms highlight its strong industry connections and credibility.

Utilization of Capital

Capital raised is primarily utilized to:

• Expand Service Offerings: Enhancing advisory capabilities and integrating advanced technologies to provide comprehensive solutions.

• Global Expansion: Establishing and maintaining offices in key international markets to support cross-border transactions.

• Talent Acquisition: Recruiting and retaining top-tier professionals with expertise in life sciences, finance, and strategy.

Pipeline Development

As an advisory firm, Locust Walk does not maintain a product pipeline. Instead, it focuses on facilitating the development and commercialization of its clients' pipelines through strategic transactions and partnerships.

Technological Platform and Innovation

Proprietary Technologies

Locust Walk has developed proprietary methodologies for market analysis and transaction structuring, enabling clients to make informed decisions and achieve optimal deal outcomes.

Significant Scientific Methods

The firm employs advanced data analytics and modeling techniques to assess market dynamics, competitive landscapes, and financial projections, providing clients with actionable insights.

AI-Driven Capabilities

Locust Walk has integrated AI-driven platforms to enhance due diligence processes, streamline workflows, and deliver faster, deeper insights to clients. This integration has led to a reduction in manual research time by over 40%, allowing the team to focus on higher-value transactions.

Leadership Team

Geoff Meyerson – CEO and Co-Founder

Geoff brings a track record of success in investment banking, venture capital, and licensing, having closed over 60 transactions, including a majority of Locust Walk’s deals. He holds an MBA in Health Care Management from the Wharton School, a Masters in Biotechnology from the University of Pennsylvania, and a BS in Economics from Duke University.

Andy Meyerson – Managing Director

Andy has extensive experience in the life sciences industry, including a legal background working with emerging growth companies and venture capital funds. He holds an MBA from New York University Stern School of Business, a JD from New York University School of Law, and a BSE in Biomedical and Electrical Engineering from Duke University.

Hiroshi Yamamoto – Managing Director

Hiroshi has over 15 years of business management expertise in pharmaceutical companies across Pan-Asia. He holds a degree in chemical engineering from Doshisha University and an MBA from the National University of Singapore.

Daniel Brog – Senior Vice President

Daniel brings broad life sciences experience across corporate development and strategy, financing, and company building to Locust Walk. He holds an MS in Biotechnology and a BS in Biology and Business from Brandeis University.

Competitor Profile

Market Insights and Dynamics

The life sciences investment banking sector is characterized by a growing demand for specialized advisory services, driven by the increasing complexity of global healthcare markets and the rapid pace of scientific innovation. Companies seek partners who can navigate regulatory landscapes, identify strategic opportunities, and secure funding to bring new therapies and technologies to market.

Competitor Analysis

Key competitors to Locust Walk include:

• Abingworth: A life sciences investment firm that invests in early-stage biopharma companies, providing capital, expertise, and strategic support.

• Danforth Advisors: Specializes in strategic advisory and operational support for the life science industry, offering services including finance and accounting, human resources, and IT.

• CM Life Sciences: Focuses on investment within the life sciences sector, providing funding and financial support to businesses in biotechnology and healthcare.

These competitors offer similar services but may differ in their specific areas of focus, geographic presence, and client engagement strategies.

Strategic Collaborations and Partnerships

Locust Walk has engaged in several notable transactions, including:

• Prazer Therapeutics and Johnson & Johnson: Served as the exclusive financial advisor to Prazer Therapeutics in an R&D collaboration with Johnson & Johnson.

• DURECT Corporation and Bausch Health: Acted as the exclusive financial advisor to DURECT Corporation in its sale to Bausch Health, involving $63 million upfront and up to $350 million in contingent value rights.

• Checkpoint Therapeutics and Sun Pharma: Advised Checkpoint Therapeutics in its sale to Sun Pharma for up to $416 million.

These collaborations highlight Locust Walk's ability to facilitate significant strategic partnerships and transactions within the life sciences sector.

Operational Insights

Locust Walk's strategic considerations include:

• Major Competitors: The firm competes with other life sciences investment banks and advisory firms, differentiating itself through its Co-founder Mentality, global presence, and integrated service offerings.

• Market Position: Locust Walk holds a strong position in the market, leveraging its expertise and network to secure high-value transactions for clients.

• Competitive Advantages: The firm's deep understanding of the life sciences industry, combined with its scientific and strategic insights, enables it to deliver tailored solutions that maximize value for clients.

Strategic Opportunities and Future Directions

Locust Walk's strategic roadmap includes:

• Expansion into Emerging Markets: Leveraging its global presence to tap into emerging biopharmaceutical hubs, particularly in Asia and Europe.

• Integration of Advanced Technologies: Continuing to incorporate AI and data analytics to enhance due diligence processes and transaction execution.